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Background: Shortened rapid eye movement (REM) sleep latency and increased REM sleep amount are presumed
biological markers of depression. These sleep alterations are also observable in several animal models of depression
as well as during the rebound sleep after selective REM sleep deprivation (RD). Furthermore, REM sleep fragmentation is
typically associated with stress procedures and anxiety. The selective serotonin reuptake inhibitor (SSRI) antidepressants
reduce REM sleep time and increase REM latency after acute dosing in normal condition and even during REM rebound
following RD. However, their therapeutic outcome evolves only after weeks of treatment, and the effects of chronic
treatment in REM-deprived animals have not been studied yet.
Results: Chronic escitalopram- (10 mg/kg/day, osmotic minipump for 24 days) or vehicle-treated rats were subjected to
a 3-day-long RD on day 21 using the flower pot procedure or kept in home cage. On day 24, fronto-parietal
electroencephalogram, electromyogram and motility were recorded in the first 2 h of the passive phase. The
observed sleep patterns were characterized applying standard sleep metrics, by modelling the transitions
between sleep phases using Markov chains and by spectral analysis.
Based on Markov chain analysis, chronic escitalopram treatment attenuated the REM sleep fragmentation
[accelerated transition rates between REM and non-REM (NREM) stages, decreased REM sleep residence time
between two transitions] during the rebound sleep. Additionally, the antidepressant avoided the frequent
awakenings during the first 30 min of recovery period. The spectral analysis showed that the SSRI prevented
the RD-caused elevation in theta (5–9 Hz) power during slow-wave sleep. Conversely, based on the aggregate
sleep metrics, escitalopram had only moderate effects and it did not significantly attenuate the REM rebound
after RD.
Conclusion: In conclusion, chronic SSRI treatment is capable of reducing several effects on sleep which might
be the consequence of the sub-chronic stress caused by the flower pot method. These data might support the
antidepressant activity of SSRIs, and may allude that investigating the rebound period following the flower pot
protocol could be useful to detect antidepressant drug response. Markov analysis is a suitable method to study
the sleep pattern.
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Disturbed sleep pattern might be involved in the onset
and course of depression [1]. Depressed patients often
suffer from insomnia [2], and the polysomnographic re-
cordings showed reduced interval between the sleep on-
set and the occurrence of the first rapid eye movement
(REM) sleep episode (i.e. REM latency) [3], enhanced
REM sleep amount, prolongation of the first REM epi-
sode, reduction of slow wave sleep (SWS), disturbed
sleep continuity and greater number of stage shifts (see
[4-6] for review). REM sleep disregulation is specific for
depression, and it has been suggested to constitute a vul-
nerability marker to relapse or reoccurrence [1]. Simi-
larly to depression, increased REM sleep pressure has
also been observed in several animal models of depres-
sion applying acute or sub-chronic stress exposure [7-9],
as well as during the recovery sleep after REM sleep
deprivation (RD) [10-13] using the single platform on
water (flower pot) protocol [14]. Besides RD, the flower
pot method definitely causes a very stressful pathological
condition due to isolation, immobilization, falling into
the water, soaking, etc. [15]. In addition, total sleep sup-
pression in different fashion produced anxiety in healthy
humans [16-18] and anxiety-like behaviour in normal
rodents [15,19,20]. Although sleep deprivation (SD) pro-
tocols may induce antidepressant effect in depressed pa-
tients and a reversal of depressive-like behaviours in
animal models of depression [21-24]. Unfortunately, the
mood improvement is only transient; relapses usually
occur with the first episode of sleep, which is associated
with high REM sleep pressure [25]. Antidepressant
medication prevented the rapid relapse into depression
after SD, and increased the efficacy of repeated SD
[23,26,27]. Sleep deprivation is not a well-established
model of depression yet, although the platform method
can provoke anhedonic behaviour [28] and many studies
have shown that it alters important pathways related to
stress (see in review: [29]); additionally, chronic sleep
loss may lead to stress-related mental disorders [30,31].
It is widely accepted that stress can cause sleep and
REM sleep fragmentation [32-34]; however, solely a few
studies have investigated the sleep phase transitions
quantitatively. Although typical sleep metrics such as the
number or the average duration of REM sleep episodes
are less than perfect tools for this purpose. One of the
reasons is that metrics are trying to grab only one-one
feature of the observed hypnograms and compare treat-
ment groups’ means simultaneously. But simultaneous
testing inflates the alpha error and also can yield results
which are very difficult to interpret in a coherent way.
Furthermore, when the experimental groups are com-
pared using metrics the degrees of freedom depend on
the number of animals in each group and they are inde-
pendent from the number of observations and from thelength of the observed period. In statistical sense, met-
rics reduce a multivariate problem to a single variate
one. This is a possible approach but generally not an ef-
ficient one in statistical sense. A possible solution to
these problems is shifting from the descriptive statistical
method to methods which connect more closely to the
underlying biological processes. The idea that hypnogram,
an apparently random sequence of WAKE-NREM-REM
episodes can be described with the help of Markov chains
goes back to the eighties [35] but the computational
constraints prevented wide spread use of this method.
Markov-modelling is essentially a regression-like proced-
ure with the distinctive feature that outcome variables are
modelled not as function-independent variables like time,
but as a function of the previous observations. The goal of
the regression procedure is to determine parameters
which predict that the animal will be in a given stage, for
example in REM stage, provided that the animal was in
NREM. Of course, additional independent variables can
be included into the model. The method is computation-
ally intensive, because the model is fitted to all observa-
tions in a single run. But exactly because of that, all
constraints between the parameters are naturally handled
and the statistical assessments are based on all observa-
tions. The result of Markov analysis is a single coherent
model which is optimal in statistical sense, because the
model parameters are obtained by maximizing the likeli-
hood. However, contrary to these appealing features,
application of Markov models is still limited in the sleep
research community [36-40]. We think that potential
reasons of this backlog are the perceived hardware re-
source requirements and the lack of appropriate Markov
module in the standard statistical program packages. But
as we demonstrate, these hardware and software limita-
tions are rapidly diminishing.
In this study, we explored how the chronically-
administered (24 days) SSRI, escitalopram affects sleep and
stage transitions during the first 2 h of rebound sleep after
a 3-day-long RD using the flower pot method. To elucidate
the transition processes between the vigilance stages, we
modelled the observed sleep stages with time-continuous
Markov chains. Unlike previous reports, we used freely
available software tools for Markovian sleep analysis. Some
practical hints about how to use these tools for hypnogram
analysis are given in Methods section. Thus, the aim of this
paper is twofold. Firstly, to provide further information on
the mechanism of action of escitalopram, and secondly to
demonstrate the applicability of hypnogram-modelling in
answering a concrete research question.
Methods
Animal maintenance
All animal experiments and housing conditions were car-
ried out in accordance with the European Community
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and the National Institutes of Health “Principles of
Laboratory Animal Care” (NIH Publications No. 85–23,
revised 1985), as well as specific national laws (the Hun-
garian Governmental Regulation on animal studies, 31
December Psychopharmacology 1998 Act). All experi-
ments were approved by the National Scientific Ethical
Committee on Animal Experimentation and permitted by
the government (Food Chain Safety and Animal Health
Directorate of the Central Agricultural Office, Permit no.
22.1/1375/7/2010). All surgery was performed under
anesthesia, and all efforts were made to minimize suffering.
Male Wistar rats (n = 27) were purchased from Animal
Facility (Semmelweis University, Budapest, Hungary). Rats,
weighing 250 to 280 g at the surgery, were kept under con-
trolled environmental conditions (temperature at 21 ± 1°C,
and a 12 h light–dark cycle starting at 10:00 A.M.). Food
and water were available ad libitum during the whole
experiment.
Surgery
Animals were equipped with electroencephalographic
(EEG) and electromyography (EMG) electrodes as de-
scribed earlier [41]. Briefly, stainless steel screw elec-
trodes were implanted epidurally over the left frontal
cortex (L: 2.0 mm and A: 2 mm to bregma) and left par-
ietal cortex (L: 2.0 mm and A: 2.0 mm to lambda) for
fronto-parietal EEG recordings. The ground electrode
was placed over the cerebellum. In addition, EMG elec-
trodes (stainless steel spring electrodes embedded in sili-
con rubber, Plastics One Inc., Roanoke, VA) were placed
in the muscles of the neck. Surgery was performed
under halothane (2%) anaesthesia (Fluotec 3) using a
Kopf stereotaxic instrument.
For the chronic SSRI treatment, osmotic minipumps
were implanted subcutaneously under the skin of the
back of each animal, slightly posterior to the scapulae,
through a 2 cm incision under halothane anaesthesia.
Drug administration
Escitalopram-oxalate solution (10 mg/kg/day, kindly
provided by Gedeon Richter Plc., dissolved in solution of
0.3 N HCl in distilled water) or its solvent was adminis-
tered via ALZET osmotic minipumps (2ML4, ALZET,
2.5 μl per hour, 28 days DURECT Corporation, USA)
continuously throughout the study. The dose of escitalo-
pram was calculated based on chronic rodent studies
demonstrating the effect of escitalopram on sleep, be-
haviour and extracellular 5-HT concentration [42-45].
Habituation
To habituate the animals to the recording conditions,
after a 7-day-long recovery period each rat was kept in a
square, glass chamber (recording cage) separately andwas attached to the polygraph by a flexible recording
cable and an electric swivel fixed above the cages, per-
mitting free movement. Habituation to the recording
conditions lasted for 7 days and rats were connected to
the cables during the whole period.
REM sleep deprivation (RD) procedure
After the habituation period, rats were detached from
the electric cable and the 72 h-long RD procedure was
performed as described earlier [11]. Briefly, the (HC) an-
imals were placed from the recording cages into regular
home cages separately, and each REM sleep-deprived
(RD) animal was placed on a round platform (diameter:
6.5 cm, surface was 0.5 cm above the water level) situ-
ated in the middle of a round water tank (diameter:
41 cm). The RD procedure was started at lights on and
finished 72 h later when HC and RD rats were placed
into the recording cages, and connected to the cables.
All animals were kept undisturbed; food and water were
available ad libitum during the whole period.
Groups
Animals were randomly divided into four groups:
Home Cage-Vehicle (HC-VEH; n = 6): 2 h polysomno-
graphic recordings were made after spending 72 h in
their own home cages; rats were treated chronically
with vehicle.
Home Cage-Escitalopram (HC-SSRI; n = 7): 2 h
polysomnographic recordings made after spending 72 h
in their own home cages; rats were treated chronically
with escitalopram.
REM sleep deprivation-Vehicle (RD-VEH; n = 7): 2 h
polysomnographic recordings were made after spending
72 h on a small platform; rats were treated chronically
with vehicle.
REM sleep deprivation-Escitalopram (RD-SSRI; n = 7):
2 h polysomnographic recordings were made after
spending 72 h on a small platform; rats were treated
chronically with escitalopram.
Sleep recording and scoring
Sleep recordings were started immediately after the RD
procedure, during a 2 hour-long period starting at the
onset of passive phase. EEG, EMG and motor activity
were recorded as described earlier [41,46,47]. Rats were
undisturbed throughout the recordings and had free ac-
cess to standard rodent chow and tap water. Data were
stored on computer for further analysis. The signals
were amplified (Coulburn Lablinc System, USA; amplifi-
cation factors approximately 5.000 for EEG and motor
activity, 20.000 for EMG), conditioned by analogue fil-
ters (Coulburn Lablinc System, USA; filtering, below
0.50 Hz and above 60 Hz at 6 dB/octave), and subjected
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Canopus, Japan) with a sampling rate of 128 Hz/channel.
The digitized signals were displayed on a monitor and
stored on the computer for further analysis. The vigi-
lance states were scored visually for 4 s epochs as fol-
lows: active wakefulness (AW), the EEG is characterized
by low amplitude activity at alpha (10–13 Hz) and beta
(14–30 Hz) frequencies accompanied by high EMG and
motor activity; passive wakefulness (PW), the EEG is
characterized by low amplitude activity at alpha (10–
13 Hz) and beta (14–30 Hz) frequencies accompanied
by low EMG activity and motor activity; light slow-wave
sleep (SWS-1), the EEG is characterized by high voltage
slow cortical waves (0.5–4 Hz) interrupted by low volt-
age fast EEG activity (spindles 6–15 Hz) accompanied by
reduced EMG and motor activity; deep slow-wave sleep
(SWS-2), the EEG is characterized by high voltage (min.
350–400 μV) slow cortical waves (0.5-4 Hz) accompan-
ied by reduced EMG and motor activity; intermediate
stage (IS) of sleep, a brief stage just prior to REM sleep
and sometimes just after it, characterized by unusual as-
sociation of high-amplitude spindles (mean 12.5 Hz) and
low-frequency (mean 5.4 Hz) theta rhythm; REM sleep,
low amplitude and high frequency EEG activity with
regular theta waves (5–9 Hz) accompanied by silent
EMG and motor activity with occasional twitching. The
polygraphic recordings were classified by sleep analysis
software (SleepSign for Animal; Kissei Comtec America
Inc., U.S.A.). Recordings were visually scored.
The treatment schedules and the experimental proto-
col are graphically summarized in Figure 1.
Modeling hypnograms as Markov chains
We modelled and compared hypnograms as time-
continuous Markov chains. Such a modelling approach
to characterize hypnograms has already been used by
others [36-39,48], and more detailed mathematical back-
ground can be found there. In short, time-continuous
Markov model assumes that the probability of the subse-
quent sleep stage depends only on the present stage and
that the probability of moving from one stage to another
exponentially increases with time. The rate of the
changes is assumed to be constant and called transitionFigure 1 Schematic illustration of the experimental design.rate. The primary interests are not transition rates them-
selves but rather how different they are compared to the
control group. In the statistical literature the relative
rates are called hazard ratios, but we feel that in the con-
text of this paper this terminology would be confusing.
Therefore we referred to hazard ratios as normalized
transition rates (NTR); the reported rates are the relative
rates compared to the HC-VEH group. If a NTR of a
group is higher than 1, it indicates that the treatment in-
creases the transition rate from one state to another
compared to the control group. If a NTR is less than 1
the given treatment inhibits the transition. Instead of
formal statistical tests we used the confidence intervals
provided by the software to declare significance. If the
confidence interval did not cover 1, we declared that the
treatment effect is statistically significant at p < 0.05 level
compared to control. Also, if the confidence intervals of
two groups are not overlapping the two groups significantly
differ at p < 0.05 level. There is another set of parameter of
interest called sojourn time. Sojourn time is essentially the
expected average time span of an event. Sojourn times have
directly interpretable physical meanings and because of
that, their absolute values are provided with the corre-
sponding 95% confidence intervals. We declared that two
sojourn times are statistically different if the corresponding
95% confidence intervals were not overlapping.
Markov-modelling is a nonlinear regression modelling
technique and it is based on numerical optimization. To
achieve convergence, we faced two limitations of the ap-
plied software. First, it had a constraint that the transi-
tion rates are constant and independent from time. This
limitation could have been overcome by visually seg-
menting the data into stationary periods, that is, when
the observed stage frequencies were relatively constant.
The time-segments were represented by an additional
factor variable in the final statistical model. The effect
of time has been factored out from the final statistical
model so the reported sojourn times and NTRs are
time independent estimates. The second limitation was
that we could achieve successful convergence only with
two or three stage models depicted in Figure 2.
Keeping in mind these limitations we proceeded in the
following way:
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servation period into an initial onset phase [starting at
lights on, lasted about 30 minutes (0–2000 s)] and a
subsequent steady phase [lasted about 90 minutes
(2001–7200 s)] because of their markedly different sleep
characteristics. In the onset phase, the frequency of
wakeful periods showed a decreasing trend. In addition,
since there were relatively few REM sleep periods in the
onset phase, any attempt to fit a three-stage [WAKE,
non-REM (NREM) and REM sleep] Markov model
failed; the optimizing algorithm did not converge. To
improve the numerical stability we merged the REM and
NREM sleep stages into one (SLEEP), so the system had
only two stages: WAKE and SLEEP. In contrast, the
prevalence of each vigilance stages was constant in the
steady phase, and the hypnogram showed much less non-
stationary features than in the onset phase. So we could fit
successfully a three-stage Markov model (WAKE, NREM
and REM) without any further segmentation.
Computation
We used the freely available R program [49] with the
help of an R package called msn [50] for the Markovian
analysis. All computations were run on a PC with 8 GB
RAM and Intel Core-I5 2500 K processor.
Standard sleep analysis
Vigilance parameters calculated in the present study
were the following:Figure 2 Markov chain representations of sleep stages and
transitions between them. The system might jump to a new state
or might remain in the current one at any time point. Straight lines
represent the transition rates from and back between two stages and
curved lines show staying in the current stage. The average time spent
between two jumps in a given stage is the sojourn time of the stage.
Four parameters (two transition rates and two sojourn times) are needed
to describe a Markov model with two states (upper panel) while fitting a
Markov model with three states (lower panel) requires the determination
of nine parameters (six transition rates and three sojourn times).– Total time spent in WAKE (AW and PW stages),
NREM (SWS-1, SWS-2 and IS stages), REM and
SLEEP (NREM plus REM sleep) in the summarized
first 2 h (1–2 h);
– Number of WAKE, NREM, REM and SLEEP
episodes in 1–2 h [an episode was defined as a
period of WAKE, NREM, REM and SLEEP lasting
for ≥4 s (1 epoch)];
– Average duration of WAKE, NREM, REM and
SLEEP episodes in 1–2 h;
– Sleep fragmentation: the sum of the number of
awakenings (either AW or PW) that disconnected
any sleep periods [51] in 1–2 h;
– REM sleep latency: the time elapsed from the start
of sleep until the first occurrence of REM sleep;
– Sleep (SWS-1) latency: the time elapsed between
light onset and the first occurrence of SWS-1;
– First REM item: the length of the first uninterrupted
REM and IS sleep period (after the first REM epoch
any IS epochs are permitted till the end of the REM
sleep item);
EEG power spectral analysis [quantitative EEG (Q-EEG)]
EEG power spectra were computed for consecutive 4 s
epochs in the frequency range 1.25 to 60 Hz (fast
Fourier transformation routine, Hanning window; fre-
quency resolution, 0.25 Hz; the range 0.5-1 Hz were
omitted from the analysis). Epochs with artefacts were
discarded on the basis of the polygraph records. Adjacent
0.25-Hz bins were summed into 1-Hz bins, and those
above 60 Hz were omitted. Bins are marked by their upper
limits, thus, 2 Hz refers to 1.25 to 2.00 Hz [46]. Frequen-
cies were binned into delta (1–4 Hz), theta (5–9 Hz), alpha
(10–13 Hz), beta (14–30 Hz) and gamma (31–60 Hz)
power bands. The power values of consecutive 4 s EEG
epochs in AW, PW, SWS-1, SWS-2, IS and REM sleep
were separately averaged in the summarized first 2 h of
sleep.
Statistical hypothesis testing
Vigilance data were subjected to two-way analysis of
variance (ANOVA) with two main factors: treatment
(VEH or SSRI) and rebound (HC or RD) followed by
Tukey’s honest significant difference test.
The EEG power spectra were evaluated by three-way
repeated measures ANOVA with three main factors
[treatment (VEH or SSRI), rebound (HC or RD) and fre-
quency bins repeated] on theta (5–9 Hz) and alpha (10–
13 Hz) frequency bands in SWS-1, respectively, followed
by Tukey’s honest significant difference test. In SWS-2,
three-way repeated measures ANOVA was used with
three main factors [treatment (VEH or SSRI), rebound
(HC or RD) and theta frequency bins (5–9 Hz), repeated]
followed by Tukey’s honest significant difference test.
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summarized first 2 h. P values less than 0.05 (p < 0.05)
were defined as statistically significant. Data in all figures
are presented as mean ± SEM of 6–7 animals per group.
For statistical analysis and graphs, Prism 6 (GraphPad
Software, Inc., USA) software was used.
Results
Markov chain analysis
Onset phase (0–2000 s)
Sojourn times and transition rates during the onset
phase are depicted in Figure 3; numerical values and sta-
tistically significant changes are represented in Table 1.
Schematic illustration of sojourn times and transition
rates in the treatment groups relative to the HC-VEH
group is shown in Figure 4.
In overall, separately, both chronic escitalopram
treatment and RD increased wakefulness; however,Figure 3 Sojourn times and normalized transition rates in the onset p
average time spent between two jumps (sojourn time; s) in A) WAKE and B
to the transition rate of HC-VEH group, which is 1) C) from WAKE to SLEEP
values and the line segments show the 95% confidence interval surroundin
home cage-chronic escitalopram treatment (HC-SSRI); REM sleep deprivatio
escitalopram treatment (RD-SSRI).when the two interventions were applied together,
these effects did not add but rather antagonized each
other.
In detail, chronic escitalopram (HC-SSRI group)
decreased the SLEEP sojourn time (by about 60%;
Figure 3B), while RD (RD-VEH group) increased the
WAKE sojourn (by more than 100%; Figure 3A) com-
pared to control, because their confidence intervals
do not overlap with that of the HC-VEH group. In
addition, the process falling into sleep was decelerated
in both the HC-SSRI and RD-VEH groups (decreased
NTRs of WAKE→ SLEEP; Figure 3C) and waking up
was promoted (increased NTRs of SLEEP→WAKE;
Figure 3D). The confidence intervals do not cover 1
(the NTR of HC-VEH group is 1), so the effect is sig-
nificant at p < 0.05 level. The RD-SSRI group did not
cause any significant difference in transition rates
compared to any other groups.hase (0–2000 s; ca. first 30 min). The estimated mean of the
) SLEEP, and the normalized transition rates (relative rates compared
and D) from SLEEP to WAKE states. Each point (●) represents the mean
g them. Groups: home cage-chronic vehicle treatment (HC-VEH);
n-chronic vehicle treatment (RD-VEH); REM sleep deprivation-chronic
Table 1 Sojourn times and Normalized Transition Rates
(NTR) in the onset phase







RD-SSRI 212.102 155.104 290.046 25.467 16.864 38.460
HC-SSRI 254.713 186.264 348.315 14.176* 9.387 21.408
RD-VEH 374.026* 264.968 527.973 21.609 13.941 33.493
HC-VEH 174.131 127.337 238.122 35.239 23.334 53.216
WAKE→ SLEEP SLEEP→WAKE
NTR L U NTR L U
RD-SSRI 0.821 0.587 1.147 1.384 0.958 1.999
HC-SSRI 0.684* 0.489 0.956 2.486* 1.791 3.450
RD-VEH 0.465* 0.323 0.670 1.631* 1.135 2.343
Sojourn time: the estimated mean of the average time span of an event;
Normalized Transition Rate (NTR): relative transition rate compared to the
HC-VEH group (NTR of the HC-VEH group is 1);
*p < 0.05, significant effect compared to the HC-VEH group;
L and U: lower and the upper limits of the corresponding 95% confidence
interval, respectively;
Normalized Transition Rate (NTR): relative transition rate compared to the
HC-VEH group (NTR of the HC-VEH group is 1);
Groups: home cage plus chronic vehicle treatment (HC-VEH); home cage plus
chronic escitalopram treatment (HC-SSRI); REM sleep deprivation plus chronic
vehicle treatment (RD-VEH); REM sleep deprivation plus chronic escitalopram
treatment (RD-SSRI).
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Sojourn times and transition rates during the steady
phase are depicted in Figure 5; numerical values and sta-
tistically significant changes are represented in Table 2.
Schematic illustration of sojourn times and transition
rates in the treatment groups relative to the HC-VEH
group is shown in Figure 4.
In overall, chronic escitalopram treatment attenuated
the RD-caused decrease in REM sojourn and the accel-
erated transitions between NREM and REM stages.
However, the SSRI had no influence on the elevated
WAKE pressure caused by RD.
In detail, the REM sleep residence time (Figure 5C)
was significantly decreased in the RD-VEH group, and
the transition rates from NREM to REM sleep and in
the backward direction (NREM↔REM, Figure 5H-I)
were increased compared to the cage control (HC-VEH
group). On the contrary, the chronic escitalopram treat-
ment alone (HC-SSRI group) doubled the length of REM
sleep sojourn (Figure 5C) and slowed down the NREM↔
REM transitions (Figure 5H-I) as well as the REM→
WAKE transitions (Figure 5G) compared to the HC-VEH
group. Regarding the RD-SSRI group, increased REM so-
journ (Figure 5C) and decreased NREM↔REM transitions
(Figure 5H-I) were found compared to the RD-VEH
group. In addition, the rate of NREM→ REM transitions
(Figure 5H) was significantly accelerated compared to the
SSRI-treated cage control (HC-SSRI group).Furthermore, WAKE sojourn time (Figure 5A) was
significantly enhanced after RD either with or without
SSRI treatment (RD-VEH vs. HC-VEH; RD-SSRI vs.
HC-SSRI and HC-VEH groups). In line with the in-
creased WAKE span, falling into sleep (WAKE→
NREM, Figure 5D) was decelerated after RD (RD-VEH
vs. HC-VEH groups and RD-SSRI vs. HC-SSRI and
HC-VEH groups). Additionally, the RD-VEH group
significantly decreased also the NREM→WAKE tran-




REM sleep parameters Based on two-way ANOVA sta-
tistics (Table 3), RD and chronic SSRI treatment had
marked effects in the total time spent in REM, REM
number and REM latency parameters (Figure 6A,B and
D, respectively). The 3-day-long RD by itself (RD-VEH
group) caused a marked REM rebound by means of
increased time spent in REM sleep (Figure 6A) and de-
creased REM onset latency time (Figure 6D) compared
to the HC-VEH group (for significant Tukey’s post hoc
comparisons see Table 3). Additionally, the RD-SSRI
group significantly decreased the REM episode duration
(Figure 6C) compared to the cage control (for significant
two-way ANOVA and Tukey’s post hoc comparisons see
Table 3).
Chronic escitalopram treatment alone (HC-SSRI
group) did not cause any significant changes. More-
over, it seems that the SSRI did not attenuate mark-
edly the REM sleep rebound, since there was no
significant interaction between the effects of RD and
chronic escitalopram treatment in any REM sleep pa-
rameters, and RD could provoke REM rebound even
besides SSRI administration [the RD-SSRI group en-
hanced the REM number (Figure 6B) and decreased the
REM latency (Figure 6D) compared to the HC-SSRI group,
Table 3].
NREM sleep parameters The RD-VEH group decreased
the total time spent in NREM sleep compared to the
cage control (for significant rebound effect and Tukey’s
post hoc comparison see Table 3). In addition, the re-
bound caused a decreasing effect in NREM sleep episode
duration (Table 3) without any significant post hoc dif-
ference between the groups.
Similarly to REM sleep, escitalopram did not influence
the effect of RD on NREM sleep (no significant rebound
by treatment interaction, Table 3).
There was no significant alteration in the following
vigilance parameters: total time spent in WAKE and
SLEEP, number of WAKE, NREM sleep and SLEEP epi-
sodes, average duration of WAKE and SLEEP episodes,
Figure 4 Illustrations of Markov chains during the onset and steady phase. Numeric data represent the relative mean values of sojourn
times and transition rates in the treatment groups compared to the mean values of the HC-VEH group (sojourn times and transition rates of the
HC-VEH group are 1). The size of circles aligns the changes in sojourn times. Thick, uninterrupted arrows represent significant increase, dashed
arrows show significant decrease and slight arrows sign no significant changes in transition speed compared to the HC-VEH group. Significant
alterations are highlighted in bold, underlined characters.
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as well as in the first REM item. ANOVA results and
mean ± SEM values assigned with all significant Tukey’s
post hoc comparisons are summarized in Table 3.
Quantitative EEG (Q-EEG) spectra
RD by itself (RD-VEH group) caused a marked elevation
on the theta (5–9 Hz) power density during both SWS-1and SWS-2 (rebound effect: F1,23 = 29.92, p < 0.0001
and F3,23 = 21.33, p < 0.001, respectively) compared to
the HC-VEH and the HC-SSRI groups (significant Tukey’s
post hoc comparisons in SWS-1 and SWS-2 are presented
in Figure 7). Chronic SSRI administration avoided this ef-
fect of RD since theta wave activity in the RD-SSRI group
was attenuated (SWS-1: treatment effect: F1,23 = 6.42, p <
0.05; treatment x rebound interaction: F1,23 = 6.94, p <
Figure 5 Sojourn times and normalized transition rates in the steady phase (2001–7200 sec; ca. 30–120 min). The estimated mean of the
average time spent between two jumps (sojourn time; s) in A) WAKE, B) NREM and C) REM sleep, and the normalized transition rates (relative
rates compared to the transition rate of HC-VEH group, which is 1) D) from WAKE to NREM, E) from NREM to WAKE, F) from WAKE to REM, G)
from REM to WAKE, H) from NREM to REM I) and from REM to NREM states. Each point (●) represents the mean values and the line segments
show the 95% confidence interval surrounding them. Groups: home cage-chronic vehicle treatment (HC-VEH); home cage-chronic escitalopram
treatment (HC-SSRI); REM sleep deprivation-chronic vehicle treatment (RD-VEH); REM sleep deprivation-chronic escitalopram treatment (RD-SSRI).
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Table 2 Sojourn times and Normalized Transition Rates (NTR) in the steady phase
Steady phase (2001–7200 s)
Group WAKE NREM REM
Sojourn time (s) L U Sojourn time (s) L U Sojourn time (s) L U
RD-SSRI 25.939*# 22.668 29.681 49.719 44.440 55.625 43.633#& 35.921 53.001
HC-SSRI 17.051 14.901 19.511 54.452 48.670 60.921 65.816* 54.183 79.946
RD-VEH 23.081* 20.442 26.061 40.459 36.157 45.273 20.999* 18.379 23.994
HC-VEH 17.199 15.031 19.681 46.758 41.793 52.312 32.844 27.039 39.896
WAKE→ NREM NREM→ WAKE
NTR L U NTR L U
RD-SSRI 0.631*# 0.528 0.755 0.836 0.696 1.005
HC-SSRI 0.970 0.819 1.150 0.938 0.800 1.099
RD-VEH 0.685* 0.573 0.819 0.831* 0.695 0.993
WAKE→ REM REM→ WAKE
NTR L U NTR L U
RD-SSRI 0.940 0.562 1.573 0.820 0.535 1.255
HC-SSRI 1.347 0.822 2.206 0.518* 0.282 0.951
RD-VEH 1.277 0.768 2.123 1.208 0.853 1.710
NREM→ REM REM→ NREM
NTR L U NTR L U
RD-SSRI 1.274#& 0.975 1.665 0.709& 0.497 1.013
HC-SSRI 0.605* 0.453 0.806 0.486* 0.297 0.796
RD-VEH 2.198* 1.739 2.779 1.796* 1.382 2.334
Sojourn time: the estimated mean of the average time span of an event;
Normalized Transition Rate (NTR): relative transition rate compared to the HC-VEH group (NTR of the HC-VEH group is 1);
L and U: lower and the upper limits of the corresponding 95% confidence interval, respectively;
*p < 0.05, significant effect compared to the HC-VEH group;
#p < 0.05, significant effect compared to the HC-SSRI group;
&p < 0.05, significant effect compared to RD-VEH group;
Groups: home cage plus chronic vehicle treatment (HC-VEH); home cage plus chronic escitalopram treatment (HC-SSRI); REM sleep deprivation plus chronic
vehicle treatment (RD-VEH); REM sleep deprivation plus chronic escitalopram treatment (RD-SSRI).
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between the RD-VEH and RD-SSRI groups, Figure 7;
SWS-2: treatment effect: F1,23 = 4.25, p = 0.0506; treat-
ment x rebound interaction: F1,23 = 4.93, p = 0.0364;
frequency x treatment interaction: F4,92 = 4.93, p < 0.01;
frequency x rebound interaction F4,92 = 3.66, p < 0.01).
In addition, REM sleep deprivation (RD-VEH group)
caused a significant elevation in the power density of
alpha frequency band (10–13 Hz) in SWS-1 [rebound
effect: F1,23 = 13.64, p < 0.05, significant Tukey’s post
hoc comparisons between RD-VEH vs. HC-VEH and
RD-VEH vs. HC-SSRI groups at 10 and 11 Hz,
Figure 7], which was interfered by chronic SSRI treat-
ment (treatment x rebound interaction: F1,23 = 4.35,
p < 0.05; frequency x rebound interaction: F3,69 =
18.45, p = 0.0000).
There were no significant changes in the EEG spectra
during AW, PW, IS and REM sleep at any frequencies
studied.Discussion
In this study we demonstrated accelerated transitions
between NREM and REM sleep stages and shortened
REM sleep sojourn after 3-day-long RD applying the
flower pot method. This REM sleep fragmentation
returned to the normal level by SSRI co-treatment, how-
ever, analysis of the aggregate sleep measures revealed
that chronic escitalopram did not influence the REM
rebound markedly. In addition, escitalopram avoided the
elevated wake pressure during the first 30 min of the
rebound period, but not later, when falling asleep
remained inhibited. The Q-EEG spectra showed that
escitalopram attenuated the elevated theta power density
during the SWS stages after RD.
Effects of chronic escitalopram treatment on REM and
NREM sleep after REM sleep deprivation
Markov-chain analysis showed that RD alone led to REM
sleep fragmentation (decreased REM sojourn; doubled
Table 3 ANOVA results and mean ±SEM values for vigilance parameters in the summarized first 2 h







F1,23 p F1,23 p F1,24 p HC-VEH RD-VEH HC-SSRI RD-SSRI
Total time spent
in stage
WAKE 0.97 0.3337 2.00 0.1703 0.89 0.3529 2063.0 ± 208.2 2991.0 ± 337.2 2823.0 ± 444.4 3006.0 ± 473.7
NREM
sleep
0.0008 0.9772 11.08 0.0029 1.14 0.2963 4325.0 ± 152.8 2921.0 ± 195.7* 3975.0 ± 430.1 3253.0 ± 367.8
REM sleep 9.18 0.0066 15.85 0.0007 0.10 0.7502 680.8 ± 58.8 1470.0 ± 160.9* 401.7 ± 69.0 940.6 ± 236.3
SLEEP 0.97 0.3335 2.00 0.1706 0.89 0.3527 5136.6 ± 208.2 4209.1 ± 337.2 4376.5 ± 444.8 4193.7 ± 473.7
Number of stage
episodes
WAKE 1.45 0.2393 2.03 0.1673 0.08 0.7757 44.5 ± 5.3 39.2 ± 4.5 40.2 ± 3.8 32.4 ± 4.5
NREM
sleep
0.96 0.3354 0.08 0.7717 <0.0001 0.9924 71.5 ± 16.5 74.8 ± 9.5 60.7 ± 6.1 63.8 ± 11.2
REM sleep 7.56 0.0117 25.22 <0.0001 0.71 0.4071 11.4 ± 0.7 16.1 ± 0.4 5.0 ± 1.1 13.43 ± 2.0##
SLEEP 0.63 0.4330 1.71 0.2035 0.26 0.6119 71.5 ± 17.3 53.1 ± 7.5 58.2 ± 6.2 50.2 ± 7.9
Average duration
of stage episodes
WAKE 0.75 0.3925 2.84 0.1024 0.15 0.7013 34.6 ± 6.0 64.5 ± 14.8 52.6 ± 12.2 71.4 ± 18.8
NREM
sleep
0.08 0.7756 5.74 0.0250 0.65 0.4284 74.27 ± 14.0 43.5 ± 7.1 69.3 ± 11.0 54.0 ± 4.7
REM sleep 0.19 0.6664 13.49 0.0015 0.04 0.8299 41.6 ± 6.8 25.1 ± 4.1 44.8 ± 4.0 26.2 ± 4.2#
SLEEP 0.05 0.8139 0.24 0.6229 0.09 0.7580 88.8 ± 16.4 91.8 ± 18.3 79.9 ± 12.2 93.0 ± 16.91
Sleep fragmentation 0.64 0.4308 1.72 0.2022 0.28 0.5997 71.0 ± 17.4 52.4 ± 7.4 57.5 ± 6.2 49.7 ± 7.8
REM sleep latency 5.05 0.0359 16.53 0.0006 0.10 0.7519 1285.6 ± 171.6 280.0 ± 57.1* 2755.4 ± 480.7 1187.4 ± 410.7#
Sleep (SWS-1) latency 0.06 0.7992 0.38 0.5385 2.54 0.1244 820.7 ± 189.5 1321.0 ± 229.3 1122 ± 257.1 903.4 ± 206.9
First REM item 0.30 0.5848 0.15 0.7005 0.50 0.4860 78.4 ± 17.2 102.0 ± 24.5 81.7 ± 20.5 74.8 ± 20.4
Significant effects of two-way ANOVA statistics are highlighted in bold.
*p < 0.05 indicates significant Tukey’s post hoc comparisons compared to the HC-VEH group; #p < 0.05 and ##p < 0.01 represent significant Tukey’s post hoc
comparisons compared to the HC-SSRI group; Data represent mean ± SEM values of 6–7 animals.
Mean values indicate time (seconds) in the cases of total time spent in stages, average duration of stages, REM sleep latency (the time elapsed from the start of
sleep until the first occurrence of REM sleep), sleep (SWS-1) latency (the time elapsed between light onset and the first occurrence of SWS-1) and first REM item
(the length of the first uninterrupted REM and IS sleep period). Means are numbers in the cases of number of stage episodes (at least 4 sec long) and sleep
fragmentation (the sum of the number of AW and PW episodes that disconnected any sleep periods).
Groups: home cage plus chronic vehicle treatment (HC-VEH); home cage plus chronic escitalopram treatment (HC-SSRI); REM sleep deprivation plus chronic
vehicle treatment (RD-VEH); REM sleep deprivation plus chronic escitalopram treatment (RD-SSRI).
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http://www.biomedcentral.com/1471-2202/15/120transitions between NREM and REM stages). On the con-
trary, chronic SSRI treatment elongated the REM sleep ep-
isodes (increased REM sojourn; inhibited traffic between
NREM and REM sleep) in home cage animals and re-
duced the accelerated REM transition processes after RD
(Figure 5C, H-I, Table 2). The standard descriptive REM
sleep parameters, REM episode number and duration
(Figure 6B-C), tended to change in the same directions,
however, these changes were not significant.
Concerning REM sleep, the pontine cholinergic (REM-
on) neurons are essential component of its generation,
and are inhibited reciprocally by monoaminergic (REM-
off ) neurons including the serotonergic cell groups [52].
After RD, higher cholinergic and lower serotonergic
neuronal activities were found [53,54]. Since a large body
of evidence indicates that major depression is associated
with an increase in cholinergic and a decrease in seroto-
nergic neurotransmission, it has been proposed that this
imbalance would be responsible for the disinhibition of
REM sleep in depressed patients [25]. In accordance with
our results found after RD, chronic mild stress for 21 daysinduced an increase in the number of transitions into
REM sleep [55]. In addition, previous data from our la-
boratory point out that although REM sleep rebound itself
is caused by the sleep deficit, the fragmentation of REM
sleep might be the consequence of the sub-chronic stress
caused by the flower pot method [11]. We can assume
that the accumulated homeostatic need for REM sleep
after RD might gradually shift the relative balance of mu-
tual inhibition between REM-on and REM-off cells, and
could be responsible for the accelerated REM sleep transi-
tions. In addition, the reverse transition processes found
after the SSRI treatment may be the result of opposite
changes in the central serotonergic tone which tend to in-
crease after escitalopram and decrease during the rebound
sleep. Since altered REM transitions returned to the nor-
mal level after escitalopram, we can speculate that the
serotonergic-cholinergic imbalance after RD might be
compensated by chronic dosing of SSRI.
Regarding aggregate sleep measures, the standard
sleep analysis showed that RD caused an elevated REM
sleep time by means of moderately increased REM
Figure 6 Aggregated REM sleep measures calculated by standard sleep analysis in the summarized first 2 h of passive phase. Changes
in the A) amount, B) episode number, C) episode duration and D) the latency time of REM sleep. Data are presented as mean ± SEM of 6–7
animals per group. *p < 0.05 means significant post hoc effects of RD-VEH group compared to the HC-VEH group; #p < 0.05 and ##p < 0.01 mean
significant post hoc effects of and RD-SSRI group compared to HC-SSRI group. Groups: home cage-chronic vehicle treatment (HC-VEH); home
cage-chronic escitalopram treatment (HC-SSRI); REM sleep deprivation-chronic vehicle treatment (RD-VEH); REM sleep deprivation-chronic
escitalopram treatment (RD-SSRI).
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http://www.biomedcentral.com/1471-2202/15/120number, and shortened REM sleep latency; additionally,
it attenuated the NREM sleep time (Figure 6, Table 3).
These results are consistent with previous reports
[11,56]. Several studies have suggested earlier that in-
creased REM number and reduced REM latency may
be the consequence of nonspecific effects of stress
[11,32,55,57]. Furthermore, stress could be a main factorFigure 7 EEG spectra during slow-wave sleep stages. Effects of chronic
on the power density of theta (5–9 Hz) and alpha (10–13 Hz) frequencies d
deep slow-wave sleep (SWS-2). Each point represents mean ± SEM values o
**p < 0.01 and ***p < 0.05 mean significant post hoc effects of RD-VEH group
mean significant post hoc effects of RD-VEH group compared to HC-SSRI grou
compared to RD-VEH group. Groups: home cage plus chronic vehicle treatme
REM sleep deprivation plus chronic vehicle treatment (RD-VEH); REM sleep dealso in the suppression of NREM sleep [58-60]. Some
studies have revealed also an enhancement in REM epi-
sode duration (in the first 3 h [12] and 2–24 h of the re-
covery period after 72 h RD [11]; in the first 6 h after
2 days of 18 h RD [56]). However, we did not find here
an enhanced REM duration after RD; in fact, there was a
tendency to decrease regarding this parameter. Since aSSRI treatment, 72 h of REM sleep deprivation and their combination
uring light slow-wave sleep (SWS-1) and on theta frequencies during
f 1-Hz bins in a 2 h recording period of 6–7 animals. *p < 0.05,
compared to the HC-VEH group; #p < 0.05, ##p < 0.01 and ###p < 0.001
p, and & p < 0.05 represents significant post hoc effect of RD-SSRI group
nt (HC-VEH); home cage plus chronic escitalopram treatment (HC-SSRI);
privation plus chronic escitalopram treatment (RD-SSRI).
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http://www.biomedcentral.com/1471-2202/15/120decrease in REM sleep duration has also been shown
after intracerebroventricular injection of corticotropin-
releasing hormone [60], it is possible that stress can
negatively affect REM episode duration. In addition, the
increment in this parameter could be the specific conse-
quence of RD and not that of stress. Considering the
abovementioned results, it is likely that during the first
2 h of rebound, stress may play the main role in sleep
regulation. Furthermore, we cannot neglect the possibil-
ity that the time interval examined here might be too
short to manifest marginal effects of RD on REM dur-
ation. Another possible cause of this discrepancy could
be that in some studies short REM attempts (a period of
REM sleep lasting for ≥16 s and not interrupted by ≥16 s
of other vigilance state) were excluded from REM sleep
episodes [11,12]. So, we evaluated our data also according
to the definition above and we found the similar effect of
RD on REM duration, but it was only a tendency to in-
crease (data not shown). This result can confirm that short
REM attempts markedly influence the results of average
duration of REM sleep episodes after RD.
As regards NREM sleep, we have to mention that dur-
ing small platform RD, beyond REM sleep, a consider-
able amount of NREM sleep might also be deprived
which can be manifested in NREM sleep rebound during
the recovery [61]. We demonstrated earlier that rats
spent significantly more time in SWS after the 3-day-
long flower pot procedure in the active phase of the
recovery day. However during the passive phase, imme-
diately after RD, a decrease in SWS sleep time was found
[11], which is in agreement with our present results.
Escitalopram by itself caused only minor changes in
REM sleep parameters which are in accordance with
previous findings (see in review: [62]). Similarly to the
effect of RD alone, our results indicated that combin-
ation of RD and chronic escitalopram also caused a
REM rebound by means of increased REM number and
decreased REM latency (Figure 6B,D). We reported earl-
ier that acute escitalopram administration (10 mg/kg,
i.p.) in rats immediately after the same RD protocol at-
tenuated the REM sleep rebound (decreased time spent
in REM and REM number, increased REM latency)
during the first 3 h of recovery sleep [12]. These results
provided evidence that acute escitalopram is still able to
reduce REM sleep despite the strong REM pressure.
Considering our present findings, this REM rebound-
reducing effect of escitalopram after RD diminishes
over chronic dosing. Previous studies indicated that the
typical REM-reducing effect of SSRI antidepressants at-
tenuates during the chronic administration, and REM
sleep amount returns towards baseline (see in review:
[62]). This process has been suggested to be mediated
mainly by the adaptation of postsynaptic serotonin (5HT)
1A receptors [63]. The desensitization of somatodendritic5-HT1A autoreceptors could also be responsible for the
therapeutic effects of both chronic SSRI treatment [64-66]
and SD therapies [26,67,68], at least in part.Effects of chronic escitalopram treatment on wakefulness
after REM sleep deprivation
The RD alone weakened the condition of stable sleep re-
sulted in more frequent awakenings during the first
30 min (onset phase). This change manifested in elon-
gated WAKE sojourn time, because the transitions to
SLEEP were inhibited and the rate of awakenings from
SLEEP was increased. The effects of chronic escitalo-
pram treatment on the SLEEP↔WAKE transitions were
qualitatively the similar to the changes after RD. Inter-
estingly, when the two interventions were applied to-
gether (RD-SSRI group), these effects were not added as
might be expected, but rather antagonized each other
(Figure 3, Table 1).
In accordance with our results, during the initial phase
of sleep rebound after long-term RD (72–96 h), animals
stay awake for approximately 30 min, when aggressive-
ness, hyperactivity, irritability and hypersexuality were
noticed, suggesting that this condition may be used to
investigate mechanisms of stress-induced insomnia [69].
Several studies suggested that the hypothalamic-pituitary-
adrenal (HPA) axis activation could be responsible for
the wake enhancement under stress exposure [58,70].
Citalopram treatment for 5 days, starting 2 days before
72 h RD using the flower pot method reversed the
anxiety-like behaviour in mice after the deprivation [19].
Furthermore, chronic administration of several antidepres-
sants reduced the responses of HPA axis activity in de-
pressed humans and rats exposed to chronic stress
[71-74]. Therefore, our results indicate that chronic anti-
depressant medication may suppress the elevated wake
pressure after RD possibly due to the reduced stress level.
In contrast to the onset phase, escitalopram treatment
did not influence the elevated wake pressure during the
further 90 min (called steady phase) of rebound sleep,
which manifested in increased WAKE sojourn time and
decelerated transitions from WAKE to NREM sleep
(Figure 5A,D, Table 2). The possible cause of this dis-
crepancy between the effects of escitalopram in the on-
set and steady phase is that wake promotion can be
mainly the consequence of stress during the initial
phase, but later the influence of RD might dominate.
However, due to the limitations of this study (e.g. ab-
sence of large platform as stress control or measuring
behaviour), firm conclusion cannot be drawn. Further-
more, beyond the serotonergic neurotransmission, RD in-
fluences other monoaminergic systems (see in review: [75])
involved in wake generation, and cannot be influenced by
the changes caused by chronic SSRI administration.
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http://www.biomedcentral.com/1471-2202/15/120Based on the aggregate sleep measures (Table 3), we
did not find any changes denoting enhanced wake pres-
sure or sleep fragmentation after RD, which is consistent
with previous reports [11,12,76].Effects of chronic escitalopram treatment on theta wave
activity during slow-wave sleep after REM sleep
deprivation
The spectral analysis of sleep established robust increases
in theta frequency power caused by RD during both SWS-
1 and SWS-2 stages, which effects were prevented by
chronic escitalopram administration (Figure 7).
In accordance with our results, enhanced theta activity
in NREM sleep has also been revealed in neonatally
clomipramin-treated rats, a model of depression, in
which increased percentage of REM sleep and shortened
REM latency onset have also been found [77]. The theta
increase in NREM sleep was associated with less restful
sleep, probably due to decreased monoaminergic signal-
ling [78]. Based on our results, chronic SSRI administra-
tion prevented the elevated theta wave activity during
SWS after RD. It suggests that this pharmacotherapy
may be efficient in reducing those effects of a stressful
SD procedure which also occur in animal models of de-
pression and may indicate a decrease in the quality of
sleep.Markov-modelling
Another implication of this study was demonstrating the
applicability of Markov chains to model hypnograms.
We were not the first to use this methodology in sleep
research, but we are not aware of any other communica-
tion where not proprietary but freely available open-
source software was used. Describing and comparing
hypnograms with Markov chains greatly facilitated our
analysis, because the parameters were easily interpret-
able in biological context and this statistical method-
ology seemed to have higher statistical power than the
standard approach. However, we came to our positive
conclusions using data of a relatively short (2 h) sleep
study, fitting time-continuous Markov model to the data
of longer time periods would be a more challenging task.
The computational time increases more than linearly
with the number of observations and finding the break-
points for the correct segmentation would demand mul-
tiple runs.
Another issue is that we used a relatively simple sleep
model with only two or three stages while in sleep re-
search, studies typically distinguish many more. In fact,
we could not fit more complex models. But none of
these limitations are due to Markov modelling method-
ology itself, but rather they reflect hardware and soft-
ware problems we faced.Conclusions
Chronic escitalopram attenuated the accelerated NREM↔
REM transitions during the rebound sleep and the in-
creased rate of awakenings in the first 30 min of the re-
bound. In addition, the RD-caused elevation in theta power
density during SWS stages was also reduced by escitalo-
pram. However, the SSRI did not suppress the REM re-
bound (increased time spent in REM, decreased REM
latency) and did not influence the decelerated transitions to
falling asleep in the steady phase (~30-120 min) of sleep.
Therefore, normalization in sleep transitions and EEG spec-
tra can be characteristic features of SSRIs and potentially
other antidepressants, which also support the validity of the
flower pot paradigm to mimic pathological conditions such
as anxiety or depression, at least regarding sleep. Finally
we showed that time-continuous Markov-modelling is a
powerful statistical tool which might allow analyzing hyp-
nograms in finer granularity and with higher statistical
power than the standard sleep metrics. Currently the
method is not without any limitations but the potential area
of application is wide and even now can be a reasonable
alternative to the standard approach.
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